Literature DB >> 14661936

Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.

Jianhua Zhang1, Yulin Deng, Jim Fang, Gordon McKay.   

Abstract

PURPOSE: This study was to develop and validate a new chiral HPLC-UV method for the quantitative analysis of enantiomeric ritalinic acid (RA) in human plasma.
METHODS: An alpha1-acid glycoprotein column was used with the mobile phase containing 0.4% acetic acid and 0.1% dimethyloctylamine, pH 3.4. The detection of enantiomeric RAs was at 220 nm.
RESULTS: A baseline separation for d- and l-RA was achieved by a separation factor of 2.08. Methylphenidate, the precursor of RA, was eluted with the front solvent, and thus does not interfere in the analysis of RA in our method. The assay was successfully applied for the in vitro analysis of enantiomeric ritalinic acids produced by human and dog plasma and dog liver.
CONCLUSIONS: Data demonstrated that the esterase(s) in human plasma metabolize d-methylphenidate faster than its l-isomer. The yielded intrinsic clearances (Clint) are 1.02 and 2.17 microl/min/mg protein, respectively, for d and l-methylphenidate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661936     DOI: 10.1023/b:pham.0000003389.77585.be

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 2.  Chiral separation of pharmaceuticals possessing a carboxy moiety.

Authors:  T Arai
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-10-09

3.  Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain.

Authors:  Y S Ding; J S Fowler; N D Volkow; S L Dewey; G J Wang; J Logan; S J Gatley; N Pappas
Journal:  Psychopharmacology (Berl)       Date:  1997-05       Impact factor: 4.530

4.  Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method.

Authors:  T Aoyama; H Kotaki; Y Honda; F Nakagawa
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

5.  A liquid-chromatographic analysis for ritalinic acid [alpha-phenyl-alpha-(2-piperidyl) acetic acid] in serum.

Authors:  S J Soldin; B M Hill; Y P Cahn; J M Swanson; J G Hill
Journal:  Clin Chem       Date:  1979-01       Impact factor: 8.327

6.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

7.  In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases--differential and enantioselective interspecies variability.

Authors:  N R Srinivas; J W Hubbard; G McKay; E M Hawes; K K Midha
Journal:  Chirality       Date:  1991       Impact factor: 2.437

8.  Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder.

Authors:  J W Hubbard; N R Srinivas; D Quinn; K K Midha
Journal:  J Pharm Sci       Date:  1989-11       Impact factor: 3.534

9.  Simultaneous detection of methylphenidate and its main metabolite, ritalinic acid, in doping control.

Authors:  A Solans; M Carnicero; R De La Torre; J Segura
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-19

10.  Pharmacology of the enantiomers of threo-methylphenidate.

Authors:  K S Patrick; R W Caldwell; R M Ferris; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

View more
  2 in total

1.  Prediction and experimental validation of enzyme substrate specificity in protein structures.

Authors:  Shivas R Amin; Serkan Erdin; R Matthew Ward; Rhonald C Lua; Olivier Lichtarge
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

2.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Hong-Jie Yuan; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Robert Malcolm; Julie A Johnson; Geri L Youngblood; Douglas H Sweet; Taimour Y Langaee; John S Markowitz
Journal:  Am J Hum Genet       Date:  2008-05-15       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.